Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head2Head: Xeomin vs Vistabel for Glabellar Frown Lines
NCT00777803Phase 3Completed
- Sponsor
- Merz
- Start
- Nov 2008
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of incobotulinumtoxinA in glabellar rhytides (2 arms), sponsored by Merz. Primary endpoint: Responder by Independent Rater's Assessment at Maximum Frown at 4 weeks. Started Nov 2008; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT00777803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777803.